XENE Xenon Pharmaceuticals Inc.

NASDAQ
$36.94

Xenon Pharmaceuticals Inc. (XENE) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $1.17 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -41.4% since its last earnings release on August 6, 2026.

Xenon Pharmaceuticals Beat Consensus Estimates
Thursday, August 6, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($1.17)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $48.26

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.

Sector

Healthcare

Industry

Biotechnology

Held By 6 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.